WallStreetZenWallStreetZen

NASDAQ: ORGS
Orgenesis Inc Stock

$0.50-0.01 (-1.96%)
Updated Apr 19, 2024
ORGS Price
$0.50
Fair Value Price
-$0.00
Market Cap
$17.20M
52 Week Low
$0.25
52 Week High
$1.50
P/E
0.26x
P/B
-0.82x
P/S
27.4x
PEG
0.19x
Dividend Yield
N/A
Revenue
$530.00k
Earnings
-$55.36M
Gross Margin
-3,084.5%
Operating Margin
-9,884.72%
Profit Margin
-10,445.5%
Debt to Equity
-1.69
Operating Cash Flow
-$15M
Beta
0.81
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ORGS Overview

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORGS ($0.50) is overvalued by 595,691.42% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ORGS ($0.50) is not significantly undervalued (595,691.42%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ORGS ($0.50) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORGS due diligence checks available for Premium users.

Be the first to know about important ORGS news, forecast changes, insider trades & much more!

ORGS News

Valuation

ORGS fair value

Fair Value of ORGS stock based on Discounted Cash Flow (DCF)
Price
$0.50
Fair Value
-$0.00
Undervalued by
594,502.61%
ORGS ($0.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORGS ($0.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORGS ($0.50) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ORGS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.26x
Industry
15.81x
Market
40.51x
ORGS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ORGS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

ORGS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.82x
Industry
5.74x

ORGS price to earnings growth (PEG)

For valuing profitable companies with growth potential
ORGS is good value based... subscribe to Premium to read more.
PEG Value Valuation

ORGS's financial health

Profit margin

Revenue
$165.0k
Net Income
-$6.6M
Profit Margin
-4,013.9%
ORGS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ORGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$14.6M
Liabilities
$35.5M
Debt to equity
-1.69
ORGS's short-term liabilities ($16.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORGS's long-term liabilities ($19.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORGS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$502.0k
Investing
-$62.0k
Financing
$1.2M
ORGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ORGS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ORGS$17.20M-2.15%0.26x-0.82x
NERV$17.34M-0.80%-0.54x-0.61x
NRBO$16.53M-2.03%-1.37x0.99x
TCRT$17.93M-8.94%-0.51x2.84x
PMCB$17.95M-3.64%-1.77x0.57x

Orgenesis Stock FAQ

What is Orgenesis's quote symbol?

(NASDAQ: ORGS) Orgenesis trades on the NASDAQ under the ticker symbol ORGS. Orgenesis stock quotes can also be displayed as NASDAQ: ORGS.

If you're new to stock investing, here's how to buy Orgenesis stock.

What is the 52 week high and low for Orgenesis (NASDAQ: ORGS)?

(NASDAQ: ORGS) Orgenesis's 52-week high was $1.50, and its 52-week low was $0.25. It is currently -66.6% from its 52-week high and 100.4% from its 52-week low.

How much is Orgenesis stock worth today?

(NASDAQ: ORGS) Orgenesis currently has 34,338,782 outstanding shares. With Orgenesis stock trading at $0.50 per share, the total value of Orgenesis stock (market capitalization) is $17.20M.

Orgenesis stock was originally listed at a price of $18.00 in Mar 13, 2012. If you had invested in Orgenesis stock at $18.00, your return over the last 12 years would have been -97.22%, for an annualized return of -25.8% (not including any dividends or dividend reinvestments).

How much is Orgenesis's stock price per share?

(NASDAQ: ORGS) Orgenesis stock price per share is $0.50 today (as of Apr 19, 2024).

What is Orgenesis's Market Cap?

(NASDAQ: ORGS) Orgenesis's market cap is $17.20M, as of Apr 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Orgenesis's market cap is calculated by multiplying ORGS's current stock price of $0.50 by ORGS's total outstanding shares of 34,338,782.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.